Advertisement
Document › Details
T-Knife Therapeutics, Inc.. (7/12/21). "Press Release: T-Knife Therapeutics Announces the Appointment of Megan Baierlein as Chief Operating Officer". San Francisco, CA & Berlin.
T-knife Therapeutics, Inc., a next-generation T cell receptor company developing a pipeline of innovative therapeutics for solid tumor patients, today announced the appointment of Megan Baierlein as chief operating officer.
“We are excited to welcome Megan to our executive leadership team,” stated Thomas M. Soloway, chief executive officer of T-knife. “Megan has over two decades of experience building and leading successful life sciences companies, overseeing strategic planning, program management, and clinical operations functions. We look forward to the significant contributions that Megan will bring to T-knife as we advance our lead candidate TK-8001, targeting MAGE-A1 positive solid tumors, toward the clinic later this year and continue to advance our leading pipeline of novel TCR-T product candidates.”
Ms. Baierlein was most recently the senior vice president and chief operating officer at Audentes Therapeutics, overseeing program management, clinical operations, and general and administrative functions. Prior to Audentes, Ms. Baierlein served as executive director of program management at Ultragenyx Pharmaceutical, Inc. From 2009 through 2013, she held management positions at BioMarin in both program management and clinical operations. Earlier in her career, Ms. Baierlein held roles of increasing responsibility at Genentech and Elan Pharmaceuticals. Ms. Baierlein holds an B.S. in Biology and Kinesiology from the University of Minnesota.
Ms. Baierlein added, “Leveraging its proprietary HuTCR platform, T-knife has rapidly generated a promising portfolio of T-cell receptor-based solid tumor product candidates with first and best-in-class potential. With its deep portfolio and world-class TCR science, there is a compelling opportunity for the company to lead the next revolution in cancer treatment. I am thrilled to join the distinguished team at T-knife and contribute to the company’s important work.”
About T-knife Therapeutics
T-knife is a next-generation T-cell receptor (TCR) company developing a pipeline of innovative therapeutics for solid tumor patients. The company leverages its proprietary humanized T-cell receptor (HuTCR) mouse platform to produce fully-human TCRs, naturally selected in-vivo for optimal affinity and specificity.
T-knife is developing a pipeline of potential first / best-in-class TCR therapeutics against targets with high unmet medical need, including cancer testis antigens, viral antigens and commonly shared neoantigens. T-knife was founded by leading T cell and immunology experts using technology developed at the Max Delbruck Center for Molecular Medicine together with Charité University Hospital in Berlin. For additional information, please visit the company’s website at www.t-knife.com.
Contact
Contact T-knife Therapeutics, Inc.
Camille Landis, CBO/CFO
[email protected]
Media Inquiries
akampion
Dr. Ludger Wess / Ines-Regina Buth
Managing Partners
[email protected]
Tel. +49 40 88 16 59 64
Tel. +49 30 23 63 27 68
Record changed: 2024-08-24 |
Advertisement
More documents for T-Knife (Group)
- [1] |transkript [Kääb, Georg]. (3/19/24). "News: Alles neu bei T-knife: Target, Molekül und Studie"....
- [2] T-Knife Therapeutics, Inc.. (1/5/22). "Press Release: T-knife Therapeutics Appoints Ronald Krasnow, J.D., as General Counsel". South San Francisco, CA & Paris....
- [3] T-Knife Therapeutics, Inc.. (8/2/21). "Press Release: T-Knife Therapeutics Announces $110 Million Series B Financing to Advance Pipeline of T-cell Receptor Therapies". San Francisco, CA & Berlin....
- [4] Andera Partners. (4/27/21). "Press Release: Andera Partners Strengthens Its Presence in the DACH Region"....
- [5] T-Knife GmbH. (1/19/21). "Press Release: T-Knife Announces Appointment of Thomas M. Soloway as Chief Executive Officer and Camille A. Landis as Chief Business Officer & Chief Financial Officer". San Francisco, CA & Berlin....
- [6] T-Knife GmbH. (9/21/20). "Press Release: T-Knife and Catalent Sign Technology Transfer and Manufacturing Agreement for Autologous T-Cell Receptor-Based Cell Therapy". Berlin & Somerset, NJ....
- [7] T-Knife GmbH. (8/6/20). "Press Release: T-Knife Completes € 66 Million Series A Financing to Develop Next-Generation T-Cell Therapies". Berlin....
To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to [email protected] and simply fill the subject line with the word »LSE Newsletter«
Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]
Advertisement
» top